芬瑞在患有IgA脏病的患者中的效果和安全性
Yanhong Guo1, Xuewen Zhang1, Silu Zhao1
1Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People's Republic of China.
Journal of inflammation research
|July 29, 2025
概括
费内伦与氨酸- ангиотензин系统抑制剂 (RASi) 结合,显著降低了IgA脏病患者的蛋白尿症. 这种组合疗法证明了有效性和安全性,为IgA病症提供了潜在的新治疗选择.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫球蛋白A神经病变 (IgA神经病变) 是一种常见的原发性淋巴细胞神经炎.
- 蛋白尿是IgA脏病进展的关键指标,也是治疗的目标.
研究的目的:
- 对于IgA脏病患者来说,回顾性评估费内伦与氨酸- ангиотензин系统抑制剂 (RASi) 结合的疗效和安全性.
- 评估菲内伦对蛋白尿和功能标志物的影响.
主要方法:
- 回顾性研究包括84名IgA脏病患者 (42名在finerenone + RASi组,42名在RASi单一治疗组).
- 随访持续时间为3个月.
- 评估的关键参数:尿蛋白肌素比率 (UPCR),估计的淋巴细胞过率 (eGFR),血清肌素,血清白蛋白,血红和血清.
主要成果:
- 与基线相比,费内伦+RASi显著降低了1个月后的UPCR27.29%和3个月后的34.17% (P < 0.001).
- 单独治疗RASi并没有显著减少蛋白尿.
- 血清和肌水平保持稳定,没有与高血症相关的不良事件.
结论:
- 与RASi结合使用的芬瑞能有效降低IgA脏病患者的蛋白尿症.
- 组合疗法在和肌素水平方面显示出良好的安全性.
- 菲内伦代表了管理IgA脏病的潜在治疗选择.
更多相关视频
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:11Renal Failure: Dose Adjustments
161
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
161
01:25Antihypertensive Drugs: Direct Renin Inhibitors
827
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
827
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
01:17Factors Affecting Renal Clearance: Renal Impairment
162
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
162
01:29Acute Kidney Injury III: Clinical Manifestations
94
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
94